Instituto do Cancer do Estado de São Paulo
Quick facts
Marketed products
- Local steroid - triamcinolone acetonide · Dermatology, Rheumatology, Immunology
Triamcinolone acetonide is a synthetic corticosteroid that suppresses local inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. - Oral steroid - predonisolone · Oncology, Immunology
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Phase 3 pipeline
- Mitomycins · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Instituto do Cancer do Estado de São Paulo portfolio CI brief
- Instituto do Cancer do Estado de São Paulo pipeline updates RSS
Frequently asked questions about Instituto do Cancer do Estado de São Paulo
What are Instituto do Cancer do Estado de São Paulo's marketed drugs?
Top marketed products include Local steroid - triamcinolone acetonide, Oral steroid - predonisolone.
What is Instituto do Cancer do Estado de São Paulo's pipeline?
Instituto do Cancer do Estado de São Paulo has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Mitomycins.
Related
- Local steroid - triamcinolone acetonide · Dermatology, Rheumatology, Immunology
- Oral steroid - predonisolone · Oncology, Immunology
- Sector hub: All tracked pharma companies